WallStSmart

Becton Dickinson and Company (BDX)vsHologic Inc (HOLX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Becton Dickinson and Company generates 431% more annual revenue ($21.92B vs $4.13B). HOLX leads profitability with a 13.2% profit margin vs 8.0%. BDX appears more attractively valued with a PEG of 1.18. BDX earns a higher WallStSmart Score of 61/100 (C+).

BDX

Buy

61

out of 100

Grade: C+

Growth: 5.3Profit: 5.5Value: 10.0Quality: 6.5
Piotroski: 6/9Altman Z: 1.49

HOLX

Buy

51

out of 100

Grade: C-

Growth: 2.7Profit: 6.5Value: 7.3Quality: 8.5
Piotroski: 5/9Altman Z: 2.37
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BDXUndervalued (+36.0%)

Margin of Safety

+36.0%

Fair Value

$282.20

Current Price

$154.13

$128.07 discount

UndervaluedFair: $282.20Overvalued
HOLXSignificantly Overvalued (-358.1%)

Margin of Safety

-358.1%

Fair Value

$16.39

Current Price

$75.41

$59.02 premium

UndervaluedFair: $16.39Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BDX3 strengths · Avg: 8.3/10
Market CapQuality
$55.84B9/10

Large-cap with strong market position

Price/BookValuation
1.7x8/10

Reasonable price relative to book value

EPS GrowthGrowth
28.6%8/10

Earnings expanding 28.6% YoY

HOLX1 strengths · Avg: 8.0/10
Operating MarginProfitability
23.0%8/10

Strong operational efficiency at 23.0%

Areas to Watch

BDX4 concerns · Avg: 3.3/10
P/E RatioValuation
25.6x4/10

Moderate valuation

Revenue GrowthGrowth
1.6%4/10

1.6% revenue growth

Return on EquityProfitability
7.0%3/10

ROE of 7.0% — below average capital efficiency

Altman Z-ScoreHealth
1.492/10

Distress zone — elevated risk

HOLX4 concerns · Avg: 3.5/10
PEG RatioValuation
1.664/10

Expensive relative to growth rate

P/E RatioValuation
31.3x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
2.5%4/10

2.5% revenue growth

EPS GrowthGrowth
-9.2%2/10

Earnings declined 9.2%

Comparative Analysis Report

WallStSmart Research

Bull Case : BDX

The strongest argument for BDX centers on Market Cap, Price/Book, EPS Growth. PEG of 1.18 suggests the stock is reasonably priced for its growth.

Bull Case : HOLX

The strongest argument for HOLX centers on Operating Margin.

Bear Case : BDX

The primary concerns for BDX are P/E Ratio, Revenue Growth, Return on Equity.

Bear Case : HOLX

The primary concerns for HOLX are PEG Ratio, P/E Ratio, Revenue Growth.

Key Dynamics to Monitor

HOLX carries more volatility with a beta of 0.73 — expect wider price swings.

HOLX is growing revenue faster at 2.5% — sustainability is the question.

BDX generates stronger free cash flow (549M), providing more financial flexibility.

Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

BDX scores higher overall (61/100 vs 51/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Becton Dickinson and Company

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Becton, Dickinson and Company, also known as BD, is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain geographies.

Visit Website →

Hologic Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Hologic, Inc. is a medical technology company primarily focused on women's health; it sells medical devices for diagnostics, surgery, and medical imaging.

Visit Website →

Want to dig deeper into these stocks?